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LICOS, a primordial costimulatory ligand?
D. Brodie*†, A.V. Collins†‡, A. Iaboni‡, J.A. Fennelly‡, L.M. Sparks‡, X-N. Xu§,
P.A. van der Merwe* and S.J. Davis‡
In mammals, the classical B7 molecules expressed on
antigen-presenting cells, B7-1 (CD80) and B7-2 (CD86),
bind the structurally related glycoproteins CD28 and
CTLA-4 (CD152), generating costimulatory signals that
regulate the activation state of T cells. A recently
identified human CD28-like protein, ICOS, also induces
costimulatory signals in T cells when crosslinked with
antibodies, but it is unclear whether ICOS is part of a
B7-mediated regulatory pathway of previously
unsuspected complexity, or whether it functions
independently and in parallel. Here, we report that,
rather than binding B7-1 or B7-2, ICOS binds a new
B7-related molecule of previously unknown function
that we call LICOS (for ligand of ICOS). At 37°C, LICOS
binds only to ICOS but, at lower, non-physiological
temperatures, it also binds weakly to CD28 and CTLA-4.
Sequence comparisons suggest that LICOS is the
homologue of a molecule expressed by avian
macrophages and of a murine protein whose
expression is induced in non-lymphoid organs by
tumour necrosis factor α (TNFα). Our results define the
components of a distinct and novel costimulatory
pathway and raise the possibility that LICOS, rather
than B7-1 or B7-2, is the contemporary homologue of a
primordial vertebrate costimulatory ligand.
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Results and discussion
ICOS is a disulphide-linked homodimeric T-cell surface
glycoprotein of relative molecular mass 55–60 kDa, whose
extracellular region, like that of CD28, consists of a single
immunoglobulin (Ig) superfamily V-set domain [1]. Unlike
CD28, which is constitutively expressed, ICOS can only be
detected on the surface of activated CD4+ and CD8+
T cells [1]. ICOS also differs from CD28 in that, when
crosslinked with antibodies, it induces the production of
the anti-inflammatory cytokine interleukin 10 (IL-10),
rather than upregulating the synthesis of IL-2 [1]. The
highly conserved amino-acid motif MYPPPY (in the single-
letter amino-acid code), required for B7 binding by CD28
and CTLA-4 [2,3], is not present in the ICOS sequence,
suggesting that it might bind a different ligand [1]. To
characterise the binding properties of ICOS, we expressed
a chimaeric form of the protein, consisting of the extracellu-
lar region of ICOS (residues 1–123) and the Fc portion of
human IgG1 (ICOS–Fc). A cDNA fragment encoding this
region of ICOS was generated by reverse transcriptase
(RT)–PCR, using whole RNA isolated from activated
human peripheral blood lymphocytes (PBL), and sub-
cloned into the pIgBOS expression vector [4]. ICOS–Fc,
secreted by 293T cells transiently transfected with the con-
struct, was purified by affinity chromatography and gel fil-
tration. Following SDS–PAGE, purified ICOS–Fc behaved
as a disulphide-linked homodimer (data not shown).
In surface plasmon resonance (SPR)-based assays per-
formed on a BIAcore apparatus [5], immobilised ICOS–Fc
bound strongly to injected anti-ICOS antibody, F44 [1],
suggesting that the chimaeric protein was correctly folded
(data not shown). When soluble monomeric forms of B7-1
and B7-2 (sB7-1 and sB7-2, respectively) were injected
over a sensor surface to which ICOS–Fc had been immo-
bilised, however, no interaction was observed at protein
concentrations that gave very good binding to CD28–Fc
and CTLA-4–Fc immobilised on adjacent sensor surfaces
(Figure 1). Moreover, in the reverse orientation, bivalent
ICOS–Fc did not bind immobilised sB7-1 or sB7-2 even
when injected at concentrations as high as 15 µM (data not
shown). These results indicate that B7-1 and B7-2 are
unlikely to be physiologically important ICOS ligands.
Given the similarities between ICOS and CD28, we used
a ‘candidate ligand’ approach to identify new potential
ICOS-binding protein(s), making the assumption that the
ligand(s) would be similar to B7. B7-related gene and
expressed sequence tag (EST) sequences were retrieved
from databases using the program BLAST [6] and from
the literature. Among these, we found an EST (GenBank
accession number R23544) initially described by Henry
et al. [7] as an uncharacterised B7-related gene they called
‘transcription unit D’. Alignments of this and other
B7-related sequences (see Figure 2 for limited compar-
isons) indicated that the new gene encoded a hypothetical
protein markedly similar to a chicken B7-like macrophage
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antigen (chCD80L [8]). O’Regan et al. [8] identified
chCD80L using murine CTLA-4–Fc in an expression-
cloning screen for putative chicken B7 homologues. The
cross-reaction between CTLA-4 and chCD80L implied
that the new human protein might also bind one or more
members of the CD28/CTLA-4/ICOS family.
A much larger cDNA sequence (EMBL accession number
AB014553), originally isolated from human brain, encom-
passing the EST and encoding a hypothetical protein
called KIAA0653, was subsequently found. Semi-quantita-
tive PCR analysis revealed that this gene is expressed at
high levels in human PBL, at somewhat lower levels in the
brain and very weakly in most other tissues (A.I. and
S.J.D., unpublished observations). After identifying a
murine homologue of this gene, sequence comparisons
suggested that the cytoplasmic-domain-encoding region of
the published human AB014553 transcript contained
unspliced intronic sequence; the sequence of cDNA re-iso-
lated from the human B cell line TZ was consistent with
this possibility (data not shown). Additional sequence
analyses revealed alternative splicing at the extreme end of
the cytoplasmic-domain-encoding regions of the murine
and human B-cell transcripts (A.I., L.M.S. and S.J.D.,
unpublished observations). We have renamed the longest
translated product of the B-cell transcripts, LICOS. The
protein sequences of human and murine LICOS are
aligned with those of chCD80L, B7-1 and B7-2 in Figure 2.
The murine sequence is identical to that of B7h, the B7-
related protein recently identified by Swallow et al. [9].
The cDNA encoding the predicted extracellular region of
LICOS was cloned from the TZ line and used to generate
a chimaeric, biotinylatable form of the protein (sLICOS),
fused to domains 3 and 4 of rat CD4. The chimaera was
expressed transiently in 293T cells using the expression
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Figure 2
Alignment of selected sequences belonging to the extended B7 subset
of the immunoglobulin superfamily. Human (h) and mouse (m) LICOS,
chCD80L (EMBL accession number Y08823), B7-1 (EMBL accession
number M27533) and B7-2 (EMBL accession number L25259) protein
sequences were aligned using the programme PILEUP (Wisconsin
Package Version 10.0, Genetics Computer Group, Wisconsin, Madison).
Residues that are identical in 5/5 or 4/5 sequences are shaded red and
those identical in 3/5 sequences are shaded blue. The hLICOS and B7-1
sequences share 34% and 24% identity with the chCD80L sequence,
indicating that hLICOS, rather than B7-1, is more likely to be the human
homologue of chCD80L. Conserved cysteines are shaded yellow. The
numbers above the alignment refer to the hLICOS sequence. The blue
and green lines over the sequences mark the predicted signal peptide
and transmembrane domain sequences of hLICOS, respectively.
Figure 1
B7-1 and B7-2 bind CD28 and CTLA-4 but not ICOS. Soluble forms
of B7-1 and B7-2 – sB7-1 (4 µM) and sB7-2 (10 µM) – were injected
over sensor surfaces to which CD22–Fc (red trace), CD28–Fc
(magenta trace), CTLA-4–Fc (green trace) or ICOS–Fc (blue trace)
were immobilised indirectly via anti-human IgG1 monoclonal antibody
R10Z8E9 as described [11]. The proteins were immobilised at the
following levels: CD22–Fc, 2,500 response units (RU); CD28–Fc,
2,200 RU; CTLA-4–Fc, 800 RU; and ICOS–Fc, 1,700 RU. The
experiment was carried out at 25°C. The responses observed when
CD22–Fc was immobilised had previously been shown to be the same
as those in flow cells to which no protein had been immobilised (data
not shown). The expression of monomeric forms of sB7-1 and sB7-2 is
described elsewhere ([11]; A.V.C., D.B., P.A.v.d.M. and S.J.D.,
unpublished observations).
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vector pEF-BOS [10], and purified from the tissue
culture supernatant by OX68 anti-CD4 affinity chromato-
graphy and gel filtration. A tetrameric form of sLICOS
(sLICOStet), generated by re-purifying the biotinylated
chimaeric protein by gel filtration after mixing it with
avidin, bound strongly to activated T cells expressing
ICOS (data not shown), indicating that the sLICOS prepa-
ration was correctly folded. In SPR-based binding assays,
monomeric sLICOS bound strongly to ICOS–Fc immo-
bilised on a sensor surface but not to CD28–Fc,
CTLA-4–Fc or the negative control protein CD22–Fc
immobilised on adjacent surfaces (Figure 3a). The affinity
of the interaction of sLICOS with ICOS–Fc was deter-
mined by saturation binding analysis (Figure 3b). A plot of
specific binding response versus sLICOS concentration
indicated that binding was saturable (data not shown), and
Scatchard analysis of the binding data (Figure 3b, inset)
yielded a solution LICOS–ICOS affinity (Kd = 4 µM)
similar to that of the CD28–B7-1 interaction [11].
The ligand-binding properties of LICOS were further char-
acterised using multivalent sLICOStet to enhance the sensi-
tivity of the analysis. At 37°C, sLICOStet bound strongly to
ICOS–Fc but not to CD28–Fc or CTLA-4–Fc, as expected
(Figure 4a). At a lower, non-physiological temperature
(25°C), however, sLICOStet bound CD28–Fc and
CTLA-4–Fc (Figure 4b, left sensogram). The cross-reactive
binding was highly specific as it was completely blocked
with antibodies that prevent B7-1 and B7-2 binding to CD28
and CTLA-4 (Figure 4b, right sensogram, for example). 
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Figure 3
LICOS binds strongly to ICOS but not CD28
or CTLA-4. (a) Injections, at 25°C, of sLICOS
(4 µM) over sensor surfaces to which
CD22–Fc (red trace), CD28–Fc (magenta
trace), CTLA-4–Fc (green trace) or ICOS–Fc
(blue trace) were immobilised. Proteins were
immobilised at the levels described in the
legend to Figure 1. (b) Injections, at 37°C, of
sLICOS at a range of concentrations (26 µM
and five twofold dilutions thereof), through a
flow cell to which ICOS–Fc was immobilised
at a level of 1,500 RU. For clarity, binding has
been corrected for background responses
observed in a control flow cell with
immobilised CD22–Fc. The inset shows linear
regression analysis of a Scatchard plot of the
ICOS–Fc–sLICOS binding data, which gave
a Kd of 4 µM.
Figure 4
Effect of temperature on the interactions of
LICOS with ICOS, CD28 and CTLA-4.
(a) Injection, at 37°C, of sLICOStet
(0.1 mg/ml) over sensor surfaces to which
CD22–Fc (red trace), CD28–Fc (magenta
trace), CTLA-4–Fc (green trace) or ICOS–Fc
(blue trace) were immobilised. Proteins were
immobilised at the levels described in the
legend to Figure 1. (b) Left sensogram:
injection, at 25°C, of sLICOStet over the
same sensor surfaces as in (a). Right
sensogram: the binding of sLICOStet to
CD28 at 25°C was completely blocked by
pretreatment with the B7-1 and B7-2 blocking
anti-CD28 antibody (CD28.1; dashed
magenta trace).
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The cross-reactivity revealed by the binding assays at low
temperatures, although clearly non-physiological, suggests
that in the course of their evolutionary history ICOS, CD28
and CTLA-4 have all been ligands for LICOS. Sequence
alignments (Figure 2) indicate that chCD80L is more likely
to be the chicken homologue of LICOS than of B7-1, and
BLAST searches have identified a chicken ICOS gene and
two other B7-like molecules, but no authentic B7-1 or B7-2
homologues (our unpublished data). Together, these obser-
vations suggest that LICOS is the contemporary homo-
logue of a protein that may have predated the classical
costimulatory molecules and functioned as a primordial
ligand for early CD28-like molecules. 
Swallow et al. [9] have recently shown that B7h enhances
T-cell proliferation through an undefined ligand distinct
from CD28 and CTLA-4. Taken with our observation that
human ICOS binds the putative human homologue of B7h,
this strongly suggests that ICOS–LICOS interactions may
generate costimulatory signals in T cells. Significantly,
although B7h is constitutively expressed on murine B cells,
its expression is upregulated in non-lymphoid tissues
treated with lipopolysaccharide (LPS), a potent activator of
the inflammatory cytokine TNFα [5]. This contrasts with
B7-1 and B7-2, which are expressed almost exclusively on
‘professional’ antigen-presenting cells. Given that ICOS is
expressed only on activated T cells and that its ligand is
readily induced in the periphery by inflammatory cytokines,
it would appear that a key function of the ICOS–LICOS
interaction is to augment local T-cell proliferation at a site of
tissue damage or infection. This contrasts with the classical
costimulatory enhancement of naïve T-cell activation medi-
ated by CD28–B7 interactions in lymph nodes [12–14].
Identification of the ICOS ligand should allow rapid
progress in understanding the immunological role of this
new costimulatory pathway in immunity and disease.
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